World Journal of Nuclear Medicine

ORIGINAL ARTICLE
Year
: 2012  |  Volume : 11  |  Issue : 3  |  Page : 105--109

Standard Operating Procedure for In-house Preparation of 131 I-rituximab for Radioimmunotherapy of Non-Hodgkin«SQ»s Lymphoma


Matthew D Pickford, J Harvey Turner 
 Department of Nuclear Medicine, The University of Western Australia, Fremantle Hospital, Fremantle WA, Australia

Correspondence Address:
J Harvey Turner
Department of Nuclear Medicine, Fremantle Hospital, Fremantle WA
Australia

A Standard Operating Procedure (SOP) has been formulated for in-house preparation, quality control, dispensing and administration of 131 I-rituximab appropriate for the safe, effective, radioimmunotherapy of non-Hodgkin lymphoma. A decade of experience of semi-automated radioiodination of rituximab in our hospital radiopharmaceutical laboratory was analysed. The methodology was then refined for safe, practical, affordable application to radioimmunotherapy of lymphoma in departments of nuclear medicine in developing countries. This SOP has the potential to be incorporated into good laboratory practice conditions appropriate for local regulatory agency requirements.


How to cite this article:
Pickford MD, Turner J H. Standard Operating Procedure for In-house Preparation of 131 I-rituximab for Radioimmunotherapy of Non-Hodgkin's Lymphoma.World J Nucl Med 2012;11:105-109


How to cite this URL:
Pickford MD, Turner J H. Standard Operating Procedure for In-house Preparation of 131 I-rituximab for Radioimmunotherapy of Non-Hodgkin's Lymphoma. World J Nucl Med [serial online] 2012 [cited 2022 Aug 11 ];11:105-109
Available from: http://www.wjnm.org/article.asp?issn=1450-1147;year=2012;volume=11;issue=3;spage=105;epage=109;aulast=Pickford;type=0